Clinical Trial Update: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial of KT-333 in adults with refractory lymphomas and solid tumors reports safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Large Granular Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• Solid Tumors
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• KT-333 (KT-333)

Snippet

Sponsor: Kymera Therapeutics, Inc. | Conditions: Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Status: COMPLETED